0.38c, page-26

In the chairmans address it states
"As a result of the increased number of sites, and significant efforts in advertising, since cohort 2, patient dosing has proceeded, and continues to proceed, according to the original plan. "

Does this not mean we are on track as ORIGINALLY planned and they arent reporting on cohorts and patient dosing as they specifically stated they wouldnt?

On they other hand they also say
"Benitec will report on progress during the trial to the Australian and US markets according to the ASX and SEC regulations if a material event, positive or negative occurs."

Does this not mean that the finding of positive efficacy is not classed as a material event?

Technically they contradict each other, as if we are on track to the original plan, then we should have efficacy data. If we dont then either way they are both material events that must be reported...

The whole ordeal is confusing me